PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 12670903-7 2003 A similar increased sensitivity to the alkylating agent methyl methanesulfonate (MMS) was also observed for siRNA-mediated ATR silencing. Methyl Methanesulfonate 56-79 ATR serine/threonine kinase Homo sapiens 123-126 28195382-0 2017 Contribution of ATM and ATR kinase pathways to p53-mediated response in etoposide and methyl methanesulfonate induced DNA damage. Methyl Methanesulfonate 86-109 ATR serine/threonine kinase Homo sapiens 24-27 21130714-1 2011 Treatment of PARP-1-expressing cells with the combination of a DNA methylating agent (MMS) and the PARP inhibitor 4-amino-1,8-naphthalimide (4-AN) leads to an ATR/Chk1-dependent S phase checkpoint and cell death by apoptosis. Methyl Methanesulfonate 86-89 ATR serine/threonine kinase Homo sapiens 159-162 20670884-2 2010 (2010) show that Mec1 (hATR) promotes the association of Slx4 and Rtt107 with Dpb11 (hTopBP1) in response to MMS-induced DNA alkylation, suggesting that Slx4 and Rtt107 might coordinate repair factors specifically at damaged replication forks. Methyl Methanesulfonate 109-112 ATR serine/threonine kinase Homo sapiens 17-21 20670884-2 2010 (2010) show that Mec1 (hATR) promotes the association of Slx4 and Rtt107 with Dpb11 (hTopBP1) in response to MMS-induced DNA alkylation, suggesting that Slx4 and Rtt107 might coordinate repair factors specifically at damaged replication forks. Methyl Methanesulfonate 109-112 ATR serine/threonine kinase Homo sapiens 23-27 19261547-2 2009 Here we show that high levels of sumoylated Rad52 are present in the mec1 sml1 and rad53 sml1 checkpoint mutants exposed to DNA-damaging agents such as methyl methanesulfonate (MMS) or the DNA replication inhibitor hydroxyurea (HU). Methyl Methanesulfonate 152-175 ATR serine/threonine kinase Homo sapiens 69-78 18375193-0 2008 The methyl methanesulfonate induced S-phase delay in XRCC1-deficient cells requires ATM and ATR. Methyl Methanesulfonate 4-27 ATR serine/threonine kinase Homo sapiens 92-95 18375193-4 2008 Using ATM- and ATR-defective cells and an ATM specific kinase inhibitor we demonstrate for the first time that the MMS-induced S-phase checkpoint requires both ATM and ATR. Methyl Methanesulfonate 115-118 ATR serine/threonine kinase Homo sapiens 15-18 18375193-4 2008 Using ATM- and ATR-defective cells and an ATM specific kinase inhibitor we demonstrate for the first time that the MMS-induced S-phase checkpoint requires both ATM and ATR. Methyl Methanesulfonate 115-118 ATR serine/threonine kinase Homo sapiens 168-171 18375193-6 2008 These results support the hypothesis that after MMS-treatment, the presence of unresolved BER intermediates gives rise to lesions that activate both ATM and ATR and that during the consequent S-phase delay, such intermediates may be repaired by a recombinational pathway which involves the Rad51 protein. Methyl Methanesulfonate 48-51 ATR serine/threonine kinase Homo sapiens 157-160 12670903-7 2003 A similar increased sensitivity to the alkylating agent methyl methanesulfonate (MMS) was also observed for siRNA-mediated ATR silencing. Methyl Methanesulfonate 81-84 ATR serine/threonine kinase Homo sapiens 123-126 12417725-4 2002 In yng2, MMS treatment causes a persistent Mec1-dependent intra-S-phase checkpoint delay characterized by slow DNA repair. Methyl Methanesulfonate 9-12 ATR serine/threonine kinase Homo sapiens 43-47